dual microtubule/RAF targeting inhibitor / Deciphera Pharmaceuticals, Ono Pharmaceutical - LARVOL DELTA

Discovery of a first-in-class dual microtubule- and RAF—targeting inhibitor (AACR 2026) - "Compound D is the first reported microtubule destabilizing agent with dual RAF activity, leading to tumor regression or growth inhibition as a single agent in preclinical models. Our data provide proof of concept for designing orally available CNS-penetrant inhibitors targeting both microtubules and RAF kinases."

Oncology • ABCB1 • KRAS